-       Report 
- July 2023
-  94 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- March 2024
-  132 Pages 
- Global 
   From       €845EUR$950USD£744GBP 
          -       Report 
- November 2021
-  1112 Pages 
- Global 
   From       €5339EUR$6,000USD£4,700GBP 
               In Situ Hybridization (ISH) is a molecular diagnostic technique used to detect and localize specific nucleic acid sequences within cells and tissues. It is used to detect gene expression, chromosomal abnormalities, and gene mutations. ISH is a powerful tool for diagnosing diseases such as cancer, genetic disorders, and infectious diseases.
ISH involves the use of labeled probes, which are complementary to the target nucleic acid sequence. The probes are hybridized to the target sequence, and the    labeled probes are detected using a variety of techniques, such as fluorescence microscopy, immunohistochemistry, and in situ PCR.
ISH is used in a variety of clinical applications, including the diagnosis of cancer, genetic disorders, and infectious diseases. It is also used in research to study gene expression, chromosomal abnormalities, and gene mutations.
Companies in the In Situ Hybridization market include Agilent Technologies, Bio-Rad Laboratories, Merck KGaA, PerkinElmer, and Thermo Fisher Scientific. Show Less   Read more